NASDAQ · Healthcare
Invest in Genmab stock from India
Indian and foreign residents can buy Genmab (GMAB) shares directly through Paasa.
By Paasa · Updated
Genmab at a glance
- Price
- $35.84+$0.27 (0.76%)
- Market cap
- $22.00B
- Day range
- $35.37 – $35.91
- P/E
- 27.75
- Dividend yield
- None
- Volume
- 3.25M
- 1 month
- +7.86%
- 6 months
- +38.81%
- YTD
- +16.37%
- 1 year
- +22.20%
- 5 years
- -17.98%
Genmab statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.7B | $21.5B | $16.5B | $14.5B | $8.4B |
| Gross profit | $3.4B | $20.5B | $16.2B | $14.5B | $8.4B |
| Operating income | $1.3B | $6.7B | $5.3B | $6.3B | $3.0B |
| Net income | $963.8M | $7.8B | $4.4B | $5.5B | $3.0B |
| Earnings per share | $1.55 | $12.14 | $6.60 | $8.34 | $4.52 |
| EBITDA | $1.3B | $9.7B | $5.9B | $7.3B | $4.2B |
| Total assets | $12.8B | $45.8B | $35.3B | $30.1B | $24.6B |
| Total debt | $5.4B | $1.0B | $770.0M | $597.0M | $425.0M |
| Cash and short-term investments | $1.7B | $21.1B | $28.1B | $22.3B | $19.3B |
| Shareholders' equity | $5.8B | $36.7B | $31.6B | $27.3B | $22.2B |
| Operating cash flow | $1.2B | $7.8B | $7.4B | $3.9B | $2.2B |
| Free cash flow | $1.1B | $7.6B | $7.0B | $3.6B | $2.0B |
| Capital expenditure | −$37.0M | −$187.0M | −$376.0M | −$317.0M | −$252.0M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Illumina | ILMN | $272.00 | $41.15B |
| Roivant Sciences | ROIV | $36.50 | $26.37B |
| Royalty Pharma | RPRX | $58.22 | $25.81B |
| Quest Diagnostics | DGX | $231.97 | $25.60B |
| Incyte | INCY | $123.20 | $24.97B |
| Tenet Healthcare | THC | $257.60 | $20.74B |
| United Therapeutics | UTHR | $481.47 | $20.44B |
| Zimmer Biomet | ZBH | $91.34 | $17.67B |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- $38.00
- High
- $43.00
- Median
- $40.00
- Consensus
- $40.33
Ratings: 13 buy · 4 hold · 1 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Genmab from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search GMAB and buy
Find Genmab by name or by its ticker, GMAB, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in Genmab from India
What Genmab does
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; A… Genmab operates in the Biotechnology industry within the Healthcare sector.
Hold a dollar asset
Genmab shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one Genmab share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Genmab stock from India?
Yes. Indian residents and NRIs can buy Genmab (GMAB) shares directly through Paasa. Genmab is listed on NASDAQ, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Genmab share?
No. You can buy part of one Genmab share and add to your position over time. One share is $35.84, and you can buy whole shares or any fraction; there is no minimum trade size.
How are Genmab dividends taxed for Indian investors?
Genmab trades on NASDAQ but is domiciled in Denmark, so any withholding on its dividends follows that country's rules rather than those of the US. What trades there is a depositary receipt over Genmab shares rather than the ordinary share itself. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Genmab shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.